CATALYSTBenzinga • 2d ago
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
Why BHVN Stock surged +6.25% Today — RQD Quant Desk Flash
$16.49 +6.25% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $16.64
Biohaven Ltd. (BHVN) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $2.49B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $16.65 (+0.94%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BHVN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY BHVN SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)
FRED Regime × Technicals: 84% of 52W Range • RSI-14 at 61.1 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$12.08-10.8% Next Q
38
Q2 (-2Q)Grade D$10.78+28.8% Next Q
41
Q3 (-1Q)Grade D$13.88+18.8% Next Q
43
CurrentGrade D$16.49-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BHVN Turnaround Squeeze
While BHVN currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.62) and Max Pain ($17.31) forces dealer call-delta covering toward $19.15.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BHVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BHVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BHVN Stock surged +6.25% Today — RQD Quant Desk Flash
Biohaven Ltd. (BHVN) surged +6.25% to $16.49, trading at 84% of its 52-week range ($7.48 – $18.24). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 84% of its 52-week range ($7.48 – $18.24) with RSI-14 at 61.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $16.49 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BHVN Headlines & Catalysts
RISK WATCHYahoo • 2d ago
Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?Biohaven (BHVN) reported a narrower quarterly net loss alongside new preclinical data on its BHV-1420 program in membranous nephropathy, giving investors two concrete updates to weigh on earnings and pipeline progress. B
MARKET WIREYahoo • 3d ago
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rar
CATALYSTBenzinga • 3d ago
Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) EstimateBiohaven (NYSE:BHVN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 50.34 percent increase over losses of $(1.47) per share from the same
CATALYSTYahoo • 3d ago
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in ea
CATALYSTYahoo • 6d ago
JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsightDelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which in
MARKET WIREYahoo • 6d ago
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous NephropathyBiohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel TRAP
MARKET WIREBenzinga • 6d ago
Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel
CATALYSTYahoo • 9d ago
Biohaven Could Transform With Troriluzole's FDA Approval, RBC SaysBiohaven (BHVN) securing approval for troriluzole could transform the company, potentially unlocking
MARKET WIREYahoo • 9d ago
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review AcceptanceBiohaven secured FDA acceptance of its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ataxia, with a planned advisory committee review and a user fee goal date set in Q1 2027. The firm a
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BHVN)
- ✓Walkthrough of BHVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BHVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.95%📐 HORIZONTAL RANGE
2026-10-30O $15.46H $16.49L $15.12C $16.49VOL 3.16M
RES: $19.54SUP: $10.24SMA50: $13.62SMA200: $12.23
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BHVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BHVN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BHVN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BHVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BHVN)
Health Care Rank #437 of 1016
⚔️ NAMS vs BHVN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BHVN vs. NAMS, ZLAB, SUPN, PGEN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Biohaven Ltd. (BHVN) ranks #437 by composite RQD confidence (46/100, grade D) and #221 by equity capitalization ($2.49B). Within this direct 5-issuer industry benchmark cohort, BHVN leads on earnings valuation at N/A trailing P/E, while SUPN leads on capital efficiency and profitability with -4.5% ROIC and 89.6% gross margin. SUPN currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with BHVN at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BHVN
ACTIVE
Biohaven Ltd. | D | 46/100 | — | — | -35.0% | +6.25% | $2.49B | Benchmark Subject |
| NAMS NewAmsterdam Pharma Company N.V. | D- | 38/100 | — | — | -35.0% | -1.47% | $2.48B | /nams-vs-bhvn → |
| ZLAB Zai Lab Limited | E | 26/100 | — | 58.3% | -35.0% | -2.95% | $2.51B | /zlab-vs-bhvn → |
| SUPN Supernus Pharmaceuticals Inc. | D+ | 56/100 | — | 89.6% | -4.5% | +1.85% | $2.43B | /supn-vs-bhvn → |
| PGEN Precigen Inc. | D- | 35/100 | — | — | -35.0% | +9.21% | $2.38B | /pgen-vs-bhvn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001935979In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biohaven Ltd. (BHVN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$738.8M, operating cash flow of -$609.4M, and free cash flow of -$610.2M (-4.0% YoY). On the balance sheet, BHVN closed FY2025 with $451.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$738.8M | -$609.4M | -$610.2M | $451.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$846.4M | -$582.5M | -$586.5M | $615.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$408.2M | -$331.7M | -$331.7M | — | — |
3. BHVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BHVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Biohaven Ltd. (NYSE: BHVN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $16.49 (+6.25% 1D, market cap $2.49B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BHVN ranks #437 in composite RQD confidence.
How does BHVN compare to NAMS and ZLAB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHVN carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NAMS (NewAmsterdam Pharma Company N.V.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B) and ZLAB (Zai Lab Limited) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.51B). Among the 5-stock peer group, BHVN leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BHVN?
Per BHVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001935979), Biohaven Ltd. generated $0 in revenue, -$738.8M in net income, and -$610.2M in free cash flow against $451.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BHVN trading relative to its 50-day, 200-day, and 52-week technical levels?
BHVN last traded at $16.49 (+6.25% on volume of 2,450,920 shares), positioning the stock +21.07% above its 50-day simple moving average ($13.62) and +34.83% above its 200-day simple moving average ($12.23). Across its 52-week range of $7.48 to $18.24, BHVN sits at the 83.7% percentile with a 14-day RSI of 61.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($14.43 to $18.55).
BHVN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BHVN stock moving today?
Why BHVN Stock surged +6.25% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.